/PRNewswire/ Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug.
/PRNewswire/ Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug.
Immutep announces investigator-initiated Phase II trial evaluating LAG-3 candidate eftilagimod alpha (efti) in soft tissue sarcoma Expansion of the efti clinical development pipeline with a new Phase II settingEfti Phase II trial awarded EUR 1.5M (AUD 2.2M) in funding as part of the Polish Medical Research Agen.
The global epirubicin market research report provides deep dive regional and country level analysis of 18+ countries across 5 key regions, 30+ key company.
Doxorubicin Market is expected to reach US$ 1,983.40 million by 2028 from US$ 1,390.64 million in 2022. It is estimated to grow at a CAGR of 6.1% from 2022.